AlzeCure Pharma AB (OSTO:ALZCUR) Notes Receivable: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ALZCUR AlzeCure Pharma AB OSTO:ALZCUR
24 GF Score
Price kr6.08
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB Notes Receivable?

AlzeCure Pharma AB OSTO:ALZCUR -3.49% 24 Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ALZCUR with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

AlzeCure Pharma AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

AlzeCure Pharma AB Notes Receivable Related Terms

AlzeCure Pharma AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB Notes Receivable Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

AlzeCure Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ALZCUR
24GF Score
AlzeCure Pharma AB OSTO:ALZCUR
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
AlzeCure Pharma AB (OSTO:ALZCUR) has a Notes Receivable of kr0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on AlzeCure Pharma AB and its competitors.
Is AlzeCure Pharma AB's Notes Receivable too high?
AlzeCure Pharma AB's current Notes Receivable is kr0.00 Mil. Overall, AlzeCure Pharma AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's Notes Receivable compare to VRTX and REGN?
AlzeCure Pharma AB's Notes Receivable of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on AlzeCure Pharma AB and its competitors. AlzeCure Pharma AB's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (OSTO:ALZCUR) has a current Notes Receivable of kr0.00 Mil. The current Notes Receivable is kr0.00 Mil. AlzeCure Pharma AB's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For AlzeCure Pharma AB (OSTO:ALZCUR), the current Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges AC6:Germany
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
24GF Score

Get the complete analysis for OSTO:ALZCUR

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.08
Price